Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis.

Saved in:
Bibliographic Details
Title: Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis.
Authors: Miyata K; Department of Pediatrics, University of California San Diego, La Jolla, California, USA atremoulet@health.ucsd.edu kmiyata@health.ucsd.edu., Bainto EV; Department of Pediatrics, University of California San Diego, La Jolla, California, USA., Sun X; Department of Family Medicine and Public Health, Division of Biostatistics & Bioinformatics, University of California San Diego, La Jolla, California, USA., Jain S; Department of Family Medicine and Public Health, Division of Biostatistics & Bioinformatics, University of California San Diego, La Jolla, California, USA., Dummer KB; Department of Pediatrics, University of California San Diego, La Jolla, California, USA.; Rady Children's Hospital San Diego, San Diego, California, USA., Burns JC; Department of Pediatrics, University of California San Diego, La Jolla, California, USA.; Rady Children's Hospital San Diego, San Diego, California, USA., Tremoulet AH; Department of Pediatrics, University of California San Diego, La Jolla, California, USA atremoulet@health.ucsd.edu kmiyata@health.ucsd.edu.; Rady Children's Hospital San Diego, San Diego, California, USA.
Source: Archives of disease in childhood [Arch Dis Child] 2023 Oct; Vol. 108 (10), pp. 833-838. Date of Electronic Publication: 2023 May 31.
Publication Type: Observational Study; Journal Article
Journal Info: Publisher: BMJ Pub. Group [etc.] Country of Publication: England NLM ID: 0372434 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-2044 (Electronic) Linking ISSN: 00039888 NLM ISO Abbreviation: Arch Dis Child Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1468-2044
DOI:10.1136/archdischild-2023-325639